These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 30355587)

  • 41. UBC
    Ecke TH; Weiß S; Stephan C; Hallmann S; Arndt C; Barski D; Otto T; Gerullis H
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513851
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combinations of urine-based tumour markers in bladder cancer surveillance.
    Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
    Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Urinary markers in the everyday diagnosis of bladder cancer.
    Dal Moro F; Valotto C; Guttilla A; Zattoni F
    Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
    Raitanen MP;
    World J Urol; 2008 Feb; 26(1):45-50. PubMed ID: 18180926
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
    Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
    Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study.
    Gontero P; Montanari E; Roupret M; Longo F; Stockley J; Kennedy A; Rodriguez O; McCracken SRC; Dudderidge T; Sieverink C; Vanié F; Allasia M; Witjes JA; Sylvester R; Colombel M; Palou J
    BJU Int; 2021 Feb; 127(2):198-204. PubMed ID: 32745350
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine.
    Zuiverloon TC; Beukers W; van der Keur KA; Munoz JR; Bangma CH; Lingsma HF; Eijkemans MJ; Schouten JP; Zwarthoff EC
    BJU Int; 2012 Mar; 109(6):941-8. PubMed ID: 21756281
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
    Beukers W; van der Keur KA; Kandimalla R; Vergouwe Y; Steyerberg EW; Boormans JL; Jensen JB; Lorente JA; Real FX; Segersten U; Orntoft TF; Malats N; Malmström PU; Dyrskjot L; Zwarthoff EC
    J Urol; 2017 Jun; 197(6):1410-1418. PubMed ID: 28049011
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma.
    Soukup V; Kalousová M; Capoun O; Sobotka R; Breyl Z; Pešl M; Zima T; Hanuš T
    Urol Int; 2015; 95(1):56-64. PubMed ID: 25662337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective study.
    Anastasi E; Maggi M; Tartaglione S; Angeloni A; Gennarini G; Leoncini PP; Sperduti I; Di Lascio G; De Stefano V; Di Pierro GB; Del Giudice F; Busetto GM; De Berardinis E; Sciarra A
    Diagn Cytopathol; 2020 Nov; 48(11):1034-1040. PubMed ID: 32562513
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer: results from the UroScreen-Study.
    Banek S; Schwentner C; Täger D; Pesch B; Nasterlack M; Leng G; Gawrych K; Bonberg N; Johnen G; Kluckert M; Gakis G; Todenhöfer T; Hennenlotter J; Brüning T; Stenzl A;
    Urol Oncol; 2013 Nov; 31(8):1656-62. PubMed ID: 22621963
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic role of survivin in urinary bladder cancer.
    Srivastava AK; Singh PK; Srivastava K; Singh D; Dalela D; Rath SK; Goel MM; Brahma Bhatt ML
    Asian Pac J Cancer Prev; 2013; 14(1):81-5. PubMed ID: 23534808
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of Bladder Epicheck® in the follow-up of non-muscle-invasive Bladder cancer: A systematic literature review.
    Caño Velasco J; Artero Fullana S; Polanco Pujol L; Lafuente Puentedura A; Subiela JD; Aragón Chamizo J; Moralejo Gárate M; Hernández Fernández C
    Actas Urol Esp (Engl Ed); 2024 Oct; 48(8):555-564. PubMed ID: 38735433
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review.
    Soorojebally Y; Neuzillet Y; Roumiguié M; Lamy PJ; Allory Y; Descotes F; Ferlicot S; Kassab-Chahmi D; Oudard S; Rébillard X; Roy C; Lebret T; Rouprêt M; Audenet F
    World J Urol; 2023 Feb; 41(2):345-359. PubMed ID: 36592175
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The follow-up of patients with non-muscle-invasive bladder cancer by urine cytology, abdominal ultrasound and urine CYFRA 21-1: a pilot study.
    Nisman B; Yutkin V; Peretz T; Shapiro A; Barak V; Pode D
    Anticancer Res; 2009 Oct; 29(10):4281-5. PubMed ID: 19846987
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.
    Karaoglu I; van der Heijden AG; Witjes JA
    World J Urol; 2014 Jun; 32(3):651-9. PubMed ID: 24166285
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence.
    Kundal VK; Pandith AA; Hamid A; Shah A; Kundal R; Wani SM
    Asian Pac J Cancer Prev; 2010; 11(5):1279-82. PubMed ID: 21198277
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review.
    Wolfs JRE; Hermans TJN; Koldewijn EL; van de Kerkhof D
    Urol Oncol; 2021 Mar; 39(3):161-170. PubMed ID: 33376063
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Can the combination of bladder ultrasonography and urinary cytodiagnosis replace cystoscopy in the diagnosis and follow-up of tumors of the bladder?].
    Cariou G; Maaraoui N; Cortesse A
    Prog Urol; 1997 Feb; 7(1):51-5. PubMed ID: 9116739
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Can repeat biopsy be skipped after initial complete resection of T1 bladder cancer? The role of a novel urinary mRNA biomarker.
    Elsawy AA; Awadalla A; Abdullateef M; Ahmed AE; Abol-Enein H
    Urol Oncol; 2021 Jul; 39(7):437.e11-437.e19. PubMed ID: 33785220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.